Meningitis - A Pipeline Analysis Report

Overview of the drug development pipeline for meningitis

Meningitis is the inflammation of the meninges. The meninges consist of three membrane layers that cover the brain and spinal cord. Meningitis occurs when the fluid surrounding the meninges gets infected. The most common cause of meningitis is viral and bacterial infections. The other causes of meningitis include cancer, chemical irritation, fungi, and drug allergies. Some of the viral and bacterial meningitis are contagious, which can be transmitted by coughing, sneezing, or close contact. Monotherapy is growingly emerging as the most effective approach for the treatment of meningitis.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for meningitis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Drug development pipeline report for meningitis: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of meningitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Beijing Minhai Biotechnology
• Beijing Tiantan Biological Products
• Beijing Zhifei Lvxhu Biopharmaceutical

Therapeutic assessment of the drug development pipeline for meningitis by route of administration

• Intramuscular
• Oral
• Intraventricular
• Unknown

The intramuscular route of administration (ROA) involves the application of the drug directly deep into the muscles and in the oral technique, the molecules are placed directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for meningitis by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for meningitis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for meningitis?
• What are the companies that are currently involved in the development of drug molecules for meningitis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.